Case Report

Postoperative Hardware-Related Infection from *Kytococcus schroeteri*: Its Association with Prosthetic Material and Hematological Malignancies—A Report of a Case and Review of Existing Literature

Aditya S. Shah 1, Prakhar Vijayvargiya 1, Sarah Jung 2, and John W. Wilson 1

1Mayo Clinic, Department of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA
2Mayo Clinic, Department of Clinical Microbiology, 200 First Street SW, Rochester, MN 55905, USA

Correspondence should be addressed to Aditya S. Shah; shah.aditya@mayo.edu

Received 10 September 2018; Revised 1 February 2019; Accepted 19 February 2019; Published 24 March 2019

1.Introduction

*Kytococcus schroeteri* is a Gram-positive coccus that was first identified by 16S rDNA analysis in 2002 [1]. It is a yellow-pigmented, aerobically growing, nonencapsulated, non-motile bacterium. The natural habitat of *K. schroeteri* is not well defined, but other members of the genus *Kytococcus* (*K. sedentarius*) have been isolated from human skin. Human infection caused by this commensal bacterium is uncommon. The first case of *K. schroeteri* infection was described in 2002, in a patient with prosthetic valve endocarditis [1]. Over the subsequent sixteen years, 18 cases have been reported. Of those, only one prior case has been reported of *K. schroeteri* causing an osteoarticular infection [2]. We discuss a case of *K. schroeteri* associated with a postsurgical hardware-related infection and review its known role in other select infection syndromes.

2. Case Report

Our patient was an 80-year-old female with a history of chronic adrenal insufficiency on oral prednisone. She suffered a left-sided intertrochanteric hip fracture and underwent a surgical implantation of a cephalomedullary nail to stabilize the femoral neck. Over the next two weeks, she developed continuous drainage from the surgical incision. On presentation to the hospital, she had ecchymoses on her left flank and serosanguinous drainage from her left hip incision. She was afebrile on admission but had an elevated white blood cell count of $29 \times 10^9/L$. An ultrasound of the hip and groin region showed a hematoma and a large left groin pseudoaneurysm from the profunda femoral artery, which was confirmed by a CT angiogram. The patient underwent coil embolization of the pseudoaneurysm and surgical wound debridement.
2.1. Investigations and Diagnosis. There were multiple positive culture results for *K. Schroeteri* on hip tissue/peri-joint tissues sent intraoperatively; and the treating infectious disease team with orthopedic infectious disease specialty focus felt this was real and constituted a prosthetic joint infection, warranting full treatment and suppression. This strain was resistant to penicillin but susceptible to clindamycin and vancomycin by Mueller–Hinton agar dilution.

2.2. Treatment. The patient was discharged to a care facility and received four weeks of daptomycin. This medication was chosen for out-of-hospital convenience of administration, owing to the once-a-day dosing. She recovered complete mobility of the joint and had no further complications in her course.

### Table 1: Reported cases of *Kytococcus* infection.

| Age (years)/Sex | Immunocompromising condition | Primary source of infection | Therapy | Outcome | Report |
|-----------------|-------------------------------|----------------------------|---------|---------|--------|
| 34/F            | None                          | Prosthetic valve endocarditis | Vancomycin, rifampin, and gentamicin | Recovered | Becker et al. [1] |
| 71/F            | Asthma on chronic prednisone therapy | Pneumonia/ bacteraemia | Ceftriaxone and ofloxacin | Deceased | Mohammedi et al. [3] |
| 73/M            | None                          | Prosthetic valve endocarditis | Teicoplanin, rifampin, and gentamicin | Recovered | Le Brun et al. [4] |
| 49/F            | None                          | Prosthetic valve endocarditis | Vancomycin and gentamicin, followed by pristinamycin and vancomycin | Recovered | Mnif et al. [5] |
| 38/F            | None                          | Prosthetic valve endocarditis | Vancomycin and gentamicin, followed by levofloxacin and rifampin | Recovered | Aepinus et al. [6] |
| 70/M            | None                          | Prosthetic valve endocarditis | Amoxicillin and gentamicin | Recovered | Renvoise et al. [7] |
| 1/M             | None                          | VP shunt                    | Vancomycin and rifampin | Recovered | Jourdain et al. [8] |
| 72/M            | None                          | Prosthetic valve endocarditis | Vancomycin, rifampin, and gentamicin | Recovered | Poyet et al. [9] |
| 64/M            | None                          | Prosthetic valve endocarditis | Vancomycin, rifampin, and gentamicin | Recovered | Yousri et al. [10] |
| 50/F            | Type 2 diabetes               | Prosthetic discitis         | Ofloxacin and rifampin | Recovered | Jacquier et al. [2] |
| 40/M            | Acute myeloid leukemia        | Pneumonia/ bacteraemia      | Vancomycin, rifampin, and gentamicin | Deceased | Hodiamont et al. [11] |
| 52/M            | Acute myeloid leukemia        | Pneumonia/ bacteraemia      | Vancomycin and ceftazidime | Deceased | Hodiamont et al. [11] |
| 43/F            | Acute myeloid leukemia        | Pneumonia and bacteraemia | Vancomycin/piperacillin/tazobactam, vancomycin/meropenem, and linezolid, discharged on TMP/SMX | Recovered | Blennow et al. [12] |
| 68/M            | Acute myeloid leukemia        | Pneumonia and bacteraemia | Vancomycin | Deceased | Nagler et al. [13] |
| 45/M            | None                          | Silicone tendon graft       | Oral doxycycline | Recovered | Chan et al. [14] |
| 53/M            | None                          | Prosthetic valve endocarditis | Daptomycin | Recovered | Liu et al. [15] |
| 3/F             | Ganglioma                     | VP shunt                    | Cefuroxime and gentamicin | Recovered | Schaumburg et al. [16] |
| 51/F            | Hairy cell leukemia           | Pneumonia and bacteraemia | Vancomycin and piperacillin/tazobactam | Deceased | Amaraneni et al. [17] |
| 80/F            | None                          | Medullary nail              | Daptomycin | Recovered | Shah et al. 2017 |

3. Discussion

The increasing number of case reports, including our own, suggests that *K. Schroeteri* can be a formidable pathogen in the appropriate host. The significance of *Kytococcus* as a human pathogen may not have been fully recognized in years past or previously misidentified as *Micrococcus* sp. Recent case reports have been able to identify this organism by molecular sequencing or using matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS) technology, as in our case. The organism grew on a blood agar plate (a trypticase soy agar plate with 5% sheep’s blood) at 35° Celsius in a CO₂-enriched environment. Colony growth showed muddy yellow-pigmented bacteria. In this report, we identify a case where *Kytococcus* was isolated from bacterial cultures and was implicated in a postsurgical hardware-related infection.
To our knowledge, this is the second known report of an osteoarticular infection caused by *K. Schroeteri*. The first known case of orthopedic infection caused by this organism was described in a case of spondylodiscitis after surgery [2]. Our patient was moderately immunocompromised as she was taking prednisone 10 mg daily for several years for her chronic adrenal insufficiency. Our review of the literature (Table 1) identified 13 other cases (Table 1) with *Kytococcus* infection that were associated with implanted foreign material: eight with prosthetic valve endocarditis, two with VP shunt infections, one with prosthetic discitis, one with silicon tendon graft infection, and one with medullary nail infection (our patient). These reports underscore the importance of evaluating for foreign body infections in patients who have a positive blood culture with *K. Schroeteri*.

Our literature review also identified 6 reported cases of *Kytococcus* pneumonia. Five of these were in conjunction with hematological malignancy (4 AML and 1 hairy cell leukemia) [11–13, 17]. The sixth patient had no hematologic condition but was moderately immunocompromised by taking prednisone 20 mg daily for 2 years for management of refractory asthma [3]. Indeed, at our institution, we have also encountered a separate and additional patient with acute myelogenous leukemia who developed fever, hypoxic respiratory failure, and consolidated infiltrates on chest imaging. *K. Schroeteri* was identified in multiple cultures from respiratory samples (unpublished).

*K. Schroeteri* is frequently misidentified as *Micrococcus* sp. because of similar morphological features. However, a distinction between the two is important since *Micrococcus* sp. is inherently susceptible to penicillin and oxacillin, whereas *Kytococcus* sp. is not. Antimicrobial susceptibility testing (AST) of *K. Schroeteri* from both our patients demonstrated in vitro resistance to penicillin and susceptibility to vancomycin and clindamycin. We also reviewed the antimicrobial susceptibility testing (AST) profile from all prior cases associated with this organism (Table 1), and the characteristic resistance to penicillin and susceptibility to vancomycin were uniform.

An important point to highlight is the fact that there are no formal established MIC breakpoints by the Clinical Laboratory Standards Institute (CLSI); therefore, the laboratory interpretation of MIC breakpoints reflecting drug susceptibility vs. resistance are implied and must be interpreted with caution. In 2015, CLSI did publish MIC breakpoints for *Micrococcus* sp. Several genera, including *Kytococcus* sp., have been included under the *Micrococcus* group for AST interpretation. While CLSI defines clinical "susceptible" vs. "resistant" *Micrococcus* MIC breakpoints for penicillin, there is no formal "resistant" MIC breakpoint defined for vancomycin. Rather, only an MIC breakpoint below which vancomycin susceptibility is reported. Therefore, vancomycin resistance is implied when reported at or above the MIC breakpoint. Whether there are clinically relevant MIC breakpoint differences between *Micrococcus* and *Kytococcus* has not been adequately determined at this time. An AST database of *Kytococcus* and *Micrococcus* isolates by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) has been developed at our center to augment the currently available CLSI reporting standards.

In summary, we describe the second known case of an osteoarticular infection from *K. Schroeteri* and reviewed the published reports of *K. Schroeteri* disease. While often considered part of the natural skin bacterial flora, human infections with *K. Schroeteri* do occur and have presented in patients with infected implanted prosthetic material and as respiratory infections in patients with significant immunosuppressive conditions, including select hematologic malignancies. *Kytococcus* appears to be susceptible to vancomycin and resistant to penicillin when grouped with *Micrococcus* by CLSI, although species-specific MIC breakpoints have not yet been formally established. The advancements made in laboratory diagnostic techniques along with rising applications of prosthetic materials may collectively enable an increased awareness of *Kytococcus* sp. as a potentially formidable human pathogen. Early identification and appropriate treatment will be critical toward successful outcomes.

**Abbreviations**

MALDI-TOF MS7: Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry

AST: Antimicrobial susceptibility testing

CLSI: Clinical Laboratory Standards Institute

MIC: Minimum inhibitory concentration

AML: Acute myelogenous leukemia

**Consent**

Appropriate consent has been obtained from the patient.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] K. Becker, P. Schumann, J. Wullenweber et al., “*Kytococcus Schroeteri* sp. nov., a novel Gram-positive actinobacterium isolated from a human clinical source,” *International Journal of Systematic and Evolutionary Microbiology*, vol. 52, no. 5, pp. 1609–1614, 2002.

[2] H. Jacquier, A. Allard, P. Richette, H. K. Ea, M. J. Sanson-Le Pors, and B. Bercot, “Postoperative spondylodiscitis due to *Kytococcus Schroeteri* in a diabetic woman,” *Journal of Medical Microbiology*, vol. 59, no. 1, pp. 127–129, 2010.

[3] I. Mohammedi, C. Berchiche, K. Becker et al., “Fatal bacteremic pneumonia,” *Journal of Infection*, vol. 51, no. 2, pp. E11–E13, 2005.

[4] C. Le Brun, J. Bouet, P. Gautier, J.-L. Avril, and O. Gaillot, “*Kytococcus Schroeteri* Endocarditis,” *Emerging Infectious Diseases*, vol. 11, no. 1, pp. 179-180, 2005.

[5] B. Mnif, I. Boujelbène, F. Mahjoubi et al., “Endocarditis due to *Kytococcus Schroeteri*: case report and review of the literature,” *Journal of Clinical Microbiology*, vol. 44, no. 3, pp. 1187–1189, 2006.
[6] C. Aepinus, E. Adolph, C. von Eiff, A. Podbielski, and M. Petzsch, "Kytococcus Schroeteri: a probably under-diagnosed pathogen involved in prosthetic valve endocarditis," Wiener Klinische Wochenschrift, vol. 120, no. 1-2, pp. 46–49, 2008.

[7] A. Renvoise, V. Roux, F. Thuny, A. Riberi, and J.-P. Casalta, "Kytococcus Schroeteri, a rare agent of endocarditis," International Journal of Infectious Diseases, vol. 12, no. 2, pp. 223–227, 2008.

[8] S. Jourdain, V. Y. Miendje Deyi, K. Musampa et al., "Kytococcus Schroeteri infection of a ventriculoperitoneal shunt in a child," International Journal of Infectious Diseases, vol. 13, no. 4, pp. e153–e155, 2009.

[9] R. Poyet, C. Martinaud, F. Pons, P. Brisou, and R. Carlioz, "Kytococcus Schroeteri infectious endocarditis," Medecine et Maladies Infectieuses, vol. 40, no. 1, pp. 51–53, 2010.

[10] T. Youssi, M. Hawari, R. Saad, and S. Langley, "Kytococcus Schroeteri prosthetic valve endocarditis," BMJ Case Reports, vol. 2010, article bcr0620103064, 2010.

[11] C. J. Hodiamont, C. Huisman, L. Spanjaard, and R. J. van Ketel, "Kytococcus Schroeteri pneumonia in two patients with a hematological malignancy," Infection, vol. 38, no. 2, pp. 138–140, 2010.

[12] O. Blennow, K. Westling, I. Froding, and V. Ozenci, "Pneumonia and bacteremia due to Kytococcus Schroeteri," Journal of Clinical Microbiology, vol. 50, no. 2, pp. 522–524, 2012.

[13] A. R. Nagler, K. A. Wanat, M. A. Bachman et al., "Fatal Kytococcus Schroeteri infection with crusted papules and distinctive histologic plump tetrads," Archives of Dermatology, vol. 147, no. 9, pp. 1119–1121, 2011.

[14] J. F. W. Chan, S. S. Y. Wong, S. S. M. Leung et al., “First report of chronic implant-related septic arthritis and osteomyelitis due to Kytococcus Schroeteri and a review of human K. Schroeteri infections,” Infection, vol. 40, no. 5, pp. 567–573, 2012.

[15] J. C. Liu, D. R. Jenkins, H. Malnick, J. Kovac, and J. Szostek, "Kytococcus Schroeteri endocarditis successfully managed with daptomycin: a case report and review of the literature," Journal of Medical Microbiology, vol. 61, no. 5, pp. 750–753, 2012.

[16] F. Schaumburg, C. Schmalstieg, B. Fiedler, A. Brentrup, H. Omran, and K Becker, "A bumpy road to the diagnosis of a Kytococcus Schroeteri shunt infection," Journal of Medical Microbiology, vol. 62, no. 1, pp. 165–168, 2013.

[17] A. Amaraneni, D. Malik, S. Jasra, S. R. Chandana, and D. Garg, "Kytococcus Schroeteri bacteremia in a patient with hairy cell leukemia: a case report and review of the literature," Case Reports in Infectious Diseases, vol. 2015, Article ID 217307, 4 pages, 2015.